(Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City featuring ...
3d
Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights
Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in ...
Key market opportunities include identifying prime locations for clinical trials, formulating strategic investments, understanding global clinical trial landscapes, and analyzing trends in trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback